1. Publications in peer-reviewed scientific journals

Diem L, Evangelopoulos MS, Karathanassis D, Natsis V, Kamber V, Hammer H, Friedli C, Chan A, Helbling A, Penner IK, Salmen A, Walther S, Stegmayer K, Hoepner R. Hypogammaglobulinemia: A contributing factor to Multiple Sclerosis Fatigue? Mult Scler Relat Disord. 2022, doi: https://doi.org/10.1016/j.msard.2022.104148

Diem L, Schwarzwald A, Friedli C, Hammer H, Gomes-Fregolente L, Warncke J, Weber L, Kamber N, Chan A, Bassetti C, Salmen A, Hoepner R. Multidimensional phenotyping of the post-COVID-19 syndrome: A Swiss survey study. CNS Neurosci Ther. 2022 doi: 10.1111/cns.13938

Stanikic M*, Salmen A*, Chan A, Kuhle J, Kaufmann M, Ammann S, Schafroth S, Rodgers S, Haag C, Pot C, Kamm CP, Zecca C, Gobbi C, Calabrese P, Manjaly ZM, von Wyl V, for the Swiss Multiple Sclerosis Registry (SMSR). Association of age and disease duration with comorbidities and disability: A study of the Swiss Multiple Sclerosis Registry. Mult Scler Relat Disord. 2022 https://doi.org/10.1016/j.msard.2022.104084 *contributed equally

Pakeerathan T, Havla J, Schwake C, Salmen A, Bigi S, Abegg M, Brügger D, Ferrazzini T, Runge AK, Breu M, Rommer P, Felipe-Rucián A, Ringelstein M, Aktas O, Wendel E, Kleiter I, Hellwig K, Kümpfel T, Thiels C, Lücke T, Gold R, Rostasy K, Ayzenberg I. Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode. J Neurol. 2022 https://doi.org/10.1007/s00415-022-11256-y

Hammer H, Kamber N, Pistor M, Diem L, Friedli C, Chan A, Hoepner R, Salmen A. Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS). Mult Scler Relat Disord. 2022 https://doi.org/10.1016/j.msard.2022.104015

Cagol A, Schaedelin S, Barakovic M, Benkert P, Todea RA, Rahmanzadeh R, Galbusera R, Lu PJ, Weigel M, Melie-Garcia L, Ruberte E, Siebenborn N, Battaglini M, Radue EW, Yaldizli Ö, Oechtering J, Sinnecker T, Lorscheider J, Fischer-Barnicol B, Müller S, Achtnichts L, Vehoff J, Disanto G, Findling O, Chan A, Salmen A, Pot C, Bridel C, Zecca C, Derfuss T, Lieb JM, Remonda L, Wagner F, Vargas MI, Du Pasquier R, Lalive PH, Pravatà E, Weber J, Cattin PC, Gobbi C, Leppert D, Kappos L, Kuhle J, Granziera C. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurol. 2022 doi:10.1001/jamaneurol.2022.1025

Diem L, Fregolente-Gomes L, Warncke JD, Hammer H, Friedli C, Kamber N, Jung S, Bigi S, Funke-Chambour M, Chan A, Bassetti CL, Salmen A, Hoepner R. Fatigue in Post-COVID-19 Syndrome: Clinical Phenomenology, Comorbidities and Association With Initial Course of COVID-19. J Cent Nerv Syst Dis. 2022 14: 1–7; DOI: 10.1177/11795735221102727

Guse K, Hagemann N, Thiele L, Remlinger J, Salmen A, Hoepner R, Keller I, Meyer P, Grandgirard D, Leib SL, Vassella E, Locatelli G, Hermann DM, Chan A. CNS Antigen-Specific Neuroinflammation Attenuates Ischemic Stroke With Involvement of Polarized Myeloid Cells. Neurol Neuroimmunol Neuroinflamm 2022;9:e1168. doi:10.1212/NXI.0000000000001168

Hammer H, Hoepner R, Friedli C, Leib SL, Suter-Riniker F, Diem L, Kamber N, Chan A, Salmen A, Kamm CP. Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients. Vaccines 2022; https://doi.org/10.3390/vaccines10060922

Hammer H, Kamber N, Friedli C, Hoepner R, Diem L, Chan A, Salmen A. Primäre ZNS-Vaskulitis - Eine Übersicht. [Primary CNS Vasculitis - An Overview]. Ther Umsch 2022 Jun;79(5):247-253. doi: 10.1024/0040-5930/a001358

Schmid R, Remlinger J, Abegg M, Hoepner R, Hoffmann R, Lukas C, Saft C, Salmen A. No optical coherence tomography changes in premanifest Huntington’s disease mutation carriers far from disease onset. Brain Behav. 2022 https://doi.org/10.1002/brb3.2592

Heesen C, Mokry C, Salmen A, Hegen H, Mäurer M, Warnke C, Gehring K, Berthele A, Meier U. Correspondence: German guideline for diagnosis and treatment of multiple sclerosis – a survey focusing neurologists in daily practice. Mult Scler Relat Dis. 2022 https://doi.org/10.1016/j.msard.2022.103828

Hoepner R, Kamm C, Friedli C, Salmen A, Chan A. Is COVID-19 severity associated with reduction in T lymphocytes in anti-CD20-treated people with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder? CNS Neuroscience & Therapeutics 2022 DOI: 10.1111/cns.13841

Oechtering J, Lincke T, Schaedelin S, Décard BF, Maceski A, Orleth A, Meier S, Willemse E, Buchmann A, Khalil M, Derfuss T, Benkert P, Heijnen I, Regeniter A, Müller S, Achtnichts L, Lalive P, Salmen A, Pot C, Gobbi C, Kappos L, Granziera C, Leppert D, Schlaeger R, Lieb JM, Kuhle J, for the Swiss MS Cohort Study. Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS. ANN NEUROL 2022;00:1–7. DOI: 10.1002/ana.26348

Hoepner R, Salmen A. Waning Humoral Immune Response to SARS-CoV-2 Vaccination with Symptomatic Infection after Initiation of Anti-CD20 Treatment in a Patient with Multiple Sclerosis. Clin. Transl. Neurosci. 2022, 6, 8. https://doi.org/10.3390/ctn6010008

Pistor M, Salmen A, Chan A, Hoepner R. COVID-19 in a Neuroimmunological Outpatient Cohort: The Bernese Experience. Clin. Transl. Neurosci. 2022, 6, 6. https://doi.org/10.3390/ctn6010006.

Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli Ö, Maceski A, Oechtering J, Achtnichts L, Conen D, Derfuss T, Lalive PH, Mueller C, Müller S, Naegelin Y, Oksenberg JR, Pot C, Salmen A, Willemse E, Kockum I, Blennow K, Zetterberg H, Gobbi C, Kappos L, Wiendl H, Berger K, Sormani MP, Granziera C, Piehl F, Leppert D, Kuhle J, for the NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 2022; 21: 246–57. doi: 10.1016/S1474-4422(22)00009-6.

Remlinger J, Madarasz A, Guse K, Hoepner R, Bagnoud M, Meli I, Feil M, Abegg M, Linington C, Shock A, Boroojerdi B, Kiessling P, Smith B, Enzmann V, Chan A, Salmen A. Anti-neonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG–Associated Experimental Autoimmune Encephalomyelitis. Neurology Neuroimmunol Neuroinflamm 2022;9:e1134. doi:10.1212/NXI.0000000000001134 

Pistor M, Hammer H, Salmen A, Hoepner R, Friedli C. Application of the "risk of ambulatory disability" (RoAD) score in a "real-world" single-center multiple sclerosis cohort. CNS Neurosci Ther. 2022; doi: 10.1111/cns.13806

Fleischer V, Ciolac D, Gonzalez-Escamilla G, Grothe M, Strauss S, Molina Galindo LS, Radetz A, Salmen A, Lukas C, Klotz L, Meuth SG, Bayas A, Paul F, Hartung HP, Heesen C, Stangel M, Wildemann B, Then Bergh F, Tackenberg B, Kümpfel T, Zettl UK, Knop M, Tumani H, Wiendl H, Gold R, Bittner S, Zipp F, Groppa S, Muthuraman M, German Competence Network Multiple Sclerosis (KKNMS). Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. Ann Neurol. 2021; doi: 10.1002/ana.26290

Mokry C, Warnke C, Gehring K, Hegen H, Salmen A, Kraemer M, Kleiter I, Fasshauer E, Scheiderbauer J, Lühmann D, Köpke S, Berthele A, Heesen C. Implementation study of the 2021 German guideline for diagnosis and treatment of multiple sclerosis. Mult Scler Relat Dis. 2022, https://doi.org/10.1016/j.msard.2021.103434

Pistor M, Hoepner AGF, Lin Y, Jung S, Bassetti CL, Chan A, Salmen A, Hoepner R. Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA's Adverse Event Reporting System. Ann Rheum Dis 2021; doi: 10.1136/annrheumdis-2021-220679

Chaloulos-Iakovidis P, Wagner F, Weber L, Diem L, Chan A, Salmen A, Friedli C, Hoepner R. Predicting conversion to multiple sclerosis in patients with radiologically isolated syndrome: a retrospective study. Ther Adv Neurol Disord. 2021, doi: 10.1177/17562864211030664

Rodgers, S.; Manjaly, Z.-M.; Calabrese, P.; Steinemann, N.; Kaufmann, M.; Salmen, A.; Chan, A.; Kesselring, J.; Kamm, C.P.; Kuhle, J.; et al. The Effect of Depression on Health-Related Quality of Life Is Mediated by Fatigue in Persons with Multiple Sclerosis. Brain Sci. 2021, 11, 751. https://doi.org/10.3390/brainsci11060751

Friedli C, Diem L, Hammer H, Kamber N, Suter-Riniker F, Leib S, Chan A, Hirzel C, Hoepner R, Salmen A. Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies. Ther Adv Neurol Disord 2021, Vol. 14: 1–3; DOI: 10.1177/17562864211016641

Diem L, Friedli C, Chan A, Salmen A, Hoepner R. Vaccine Hesitancy in Patients With Multiple Sclerosis - Preparing for the SARS-CoV-2 Vaccination Challenge. Neurol Neuroimmunol Neuroinflamm 2021;8:e991. doi:10.1212/NXI.0000000000000991

Gili-Kovács J, Hoepner R, Salmen A, Bagnoud M, Gold R, Chan A, Briner M. An algorithm using clinical data to predict the optimal individual glucocorticoid dosage to treat multiple sclerosis relapses. Ther Adv Neurol Disord. 2021. doi: 10.1177/17562864211020074

Rodgers S, Calabrese P, Ajdacic-Gross V, Steinemann N, Kaufmann M, Salmen A, Manjaly ZM, Kesselring J, Kamm CP, Kuhle J, Chan A, Gobbi C, Zecca C, Müller S, von Wyl V. Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population? J Psychosom Res 2021 Feb 16;144:110402. doi: 10.1016/j.jpsychores.2021.110402

Diem L, Hoepner R, Bagnoud M, Salmen A, Chan A, Friedli C. Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature. Journal of Neuroimmunology 353 (2021), https://doi.org/10.1016/j.jneuroim.2021.577505

Rodriguez B, Hoepner R, Salmen A, Kamber N, Z’Graggen WJ. Immunomodulatory treatment in postural tachycardia syndrome: A case series. Eur J Neurol. 2021;00:1–6. DOI: 10.1111/ene.14711

Diem L, Bürge M, Leichtle A, Hakim A, Chan A, Salmen A, Evangelopoulos ME, Hoepner R. Pathological cerebrospinal fluid protein concentration and albumin quotient at relapse predicts short-term disability progression in multiple sclerosis: a retrospective single center observational study. Ther Adv Neurol Disord 2020, Vol. 13: 1–7. DOI: 10.1177/1756286420975909

Ostkamp P, Salmen A, Pignolet B, Görlich D, Andlauer TFM, Schulte-Mecklenbeck A, Gonzalez-Escamilla G, Bucciarelli F, Gennero I, Breuer J, Antony G, Schneider-Hohendorf T, Mykicki N, Bayas A, Then Bergh F, Bittner S, Hartung HP, Friese MA, Linker RA, Luessi F, Lehmann-Horn K, Mühlau M, Paul F, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber F, Wildemann B, Zettl UK, Ziemann U, Müller-Myhsok B, Kümpfel T, Klotz L, Meuth SG, Zipp F, Hemmer B, Hohlfeld R, Brassat D, Gold R, Gross CC, Lukas C, Groppa S, Loser K, Wiendl H, Schwab N, and on behalf of the German Competence Network Multiple Sclerosis (KKNMS) and the BIONAT Network. Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. PNAS 2021Vol. 118 No. 1 e2018457118; https://doi.org/10.1073/pnas.2018457118

Veselaj K, Kamber N, Briner M, Friedli C, Diem L, Guse K, Miclea A, Wiest R, Wagner F, Grabe H, Abegg M, Horn MP, Bigi S, Chan A, Hoepner R and Salmen A. Evaluation of diagnostic criteria and red flags of myelin oligodendrocyte glycoprotein encephalomyelitis in a clinical routine cohort. CNS Neurosci Ther. 2020;00:1–13. DOI: 10.1111/cns.13461

Bagnoud M, Briner M, Remlinger J, Meli I, Schuetz S, Pistor M, Salmen A, Chan A, Hoepner R. c-Jun N-Terminal Kinase as a Therapeutic Target in Experimental Autoimmune Encephalomyelitis Cells 2020, 9, 2154; doi:10.3390/cells9102154

Vicini R, Brügger D, Abegg M, Salmen A, Grabe HM. Differences in morphology and visual function of myelin oligodendrocyte glycoprotein antibody and multiple sclerosis associated optic neuritis. J Neurol 2020 (online first), https://doi.org/10.1007/s00415-020-10097-x

Dietmann A, Horn MP, Schinkelshoek M, Fronczek R, Salmen A, Bargiotas P, Lammers GJ, Khatami R, Bassetti CLA. Conventional autoantibodies against brain antigens are not routinely detectable in serum and CSF of narcolepsy type 1 and 2 patients. Sleep Medicine 2020, https://doi.org/10.1016/j.sleep.2020.08.001

Lehmann AI, Rodgers S, Kamm CP, Mettler M, Steinemann N, Ajdacic‑Gross V, Kaufmann M, Kesselring J, Calabrese P, Salmen A, Gobbi C, Zecca C, Bauer GF, von Wyl V. Factors associated with employment and expected work retention among persons with multiple sclerosis: findings of a cross‑sectional citizen science study. J Neurol 2020 (online first), https://doi.org/10.1007/s00415-020-09973-3 

Bittner S, Steffen F, Uphaus T, Muthuramana M, Fleischer V, Salmen A, Luessi F, Berthele A, Klotz L, Meuth SG, Bayas A, Paul F, Hartung HP, Linker R, Heesen C, Stangel M, Wildemann B, Then Bergh F, Tackenberg B, Kuempfel T, Weber F, Zettl UK, Ziemann U, Tumani H, Groppa S, Muehlau M, Lukas C, Hemmer B, Wiendl H, Gold R, Zipp F, KKNMS consortium. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine 56 (2020) 102807; https://doi.org/10.1016/j.ebiom.2020.102807

Abrahamyan S, Eberspächer B, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Schroeder C, Grüter T, Tackenberg B, Paul F, Then-Bergh F, Kümpfel T, Weber F, Stangel M, Bayas A, Wildemann B, Heesen C, Zettl U, Warnke C, Antony G, Hessler N, Wiendl H, Bittner S, Hemmer B, Gold R, Salmen A and Ruprecht K. Complete Epstein-Barr Virus Seropositivity in a Large Cohort of Patients With Early Multiple Sclerosis. J Neurol Neurosurg Psychiatry 2020, doi: 10.1136/jnnp-2020-322941 

Engel S, Graetz C, Salmen A, Muthuraman M, Toenges G, Ambrosius B, Bayas A, Berthele A, Heesen C, Klotz L, Kümpfel T, Linker RA, Meuth SG, Paul F, Stangel M, Tackenberg B, Then Bergh F, Tumani H, Weber F, Wildemann B, Zettl UK, Antony G, Bittner S, Groppa S, Hemmer B, Wiendl H, Gold R, Zipp F, Lill CM, Luessi F, for the German Competence Network of Multiple Sclerosis. Is APOE «4 associated with cognitive performance in early MS? Neurol Neuroimmunol Neuroinflamm 2020;7:e728. doi:10.1212/NXI.0000000000000728 

Kaufmann M, Salmen A, Barina L, Puhan MA, Calabrese P, Kamm CP, Gobbi C, Kuhle J, Manjaly ZM, Ajdacic-Gross V, Schafroth S, Bottignole B, Ammann S, Zecca C, D'Souza M, von Wyl V, for the Swiss Multiple Sclerosis Registry (SMSR). Development and validation of the self-reported disability status scale (SRDSS) to estimate EDSS-categories. Mult Scler Relat Dis. 42 (2020) 102148. https://doi.org/10.1016/j.msard.2020.102148

Kaufmann M, Puhan MA, Salmen A, Kamm CP, Manjaly Z-M, Calabrese P, Schippling S, Müller S, Kuhle J, Pot C, Gobbi C, Steinemann N, von Wyl V. 60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments. Front. Neurol. 2020; 11:156. doi: 10.3389/fneur.2020.00156

Müller A, Salmen A, Aebi S, de Gouveia L, von Gottberg A, Hathaway LJ. Pneumococcal serotype determines growth and capsule size in human cerebrospinal fluid. BMC Microbiology 2020; 20:16. https://doi.org/10.1186/s12866-020-1700-7

Diem L, Daponte A, Findling O, Miclea A, Briner M, Salmen A, Gold R, Kilidireas C, Chan A, Evangelopoulos ME, Hoepner R. Dimethyl fumarate vs fingolimod following different pretreatments - A retrospective study. Neurol Neuroimmunol Neuroinflamm 2020; 7:e660. doi:10.1212/NXI.0000000000000660

Thiele née Schrewe L, Guse K, Tietz S, Remlinger J, Demir S, Pedreiturria X, Hoepner R, Salmen A, Pistor M, Turner T, Engelhardt B, Hermann DM, Lühder F, Wiese S, Chan A. Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis. J Neuroinflammation 2020; 17:9. https://doi.org/10.1186/s12974-019-1677-z 

Heitmann H; Haller B; Tiemann, L; Mühlau M; Berthele A; Tölle TR; Salmen A; Ambrosius B; Bayas A; Asseyer S; Hartung HP; Heesen C; Stangel M; Wildemann B; Haars S; Groppa S; Luessi F; Kümpfel T; Nischwitz S; Meuth SG; Klotz L; Linker RA; Zettl UK; Ziemann U; Tumani H; Tackenberg B; Zipp F; Wiendl H; Gold R; Hemmer B; Ploner M. Longitudinal prevalence and determinants of pain in multiple sclerosis results from the German National Multiple Sclerosis Cohort study. PAIN 2020. doi: 10.1097/j.pain.0000000000001767

McKinley R, Wepfer R, Grunder L, Aschwanden F, Fischer T, Friedli C, Muri R, Rummel C, Verma R, Weisstanner C, Wiestler B, Berger C, Eichinger P, Muhlau M, Reyes M, Salmen A, Chan A, Wiest R, Wagner F. Automatic detection of lesion load change in Multiple Sclerosis using convolutional neural networks with segmentation confidence. NeuroImage: Clinical 25 (2020) 102104; https://doi.org/10.1016/j.nicl.2019.102104

Skorupka N, Miclea A, Jalowiec KA, Bocksrucker C, Kamber N, Chan A, Mansouri Taleghani B, Hoepner R and Salmen A. Visual Outcomes of Plasma Exchange Treatment of Steroid-Refractory Optic Neuritis: A Retrospective Monocentric Analysis. Transfus Med Hemother 2019, DOI: 10.1159/000504027

Kamm CP, Barin L, Gobbi C, Pot C, Calabrese P, Salmen A, Achtnichts L, Kesselring J, Puhan MA, von Wyl V, For the Swiss Multiple Sclerosis Registry (SMSR). Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study. J Neurol. 2019, https://doi.org/10.1007/s00415-019-09563-y

Zoehner G, Miclea A, Salmen A, Kamber N, Diem L, Friedli C, Bagnoud M, Ahmadi F, Briner M, Sédille-Mostafaie N, Kilidireas C, Stefanis L, Chan A, Hoepner R, Evangelopoulos ME. Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course. Ther Adv Neurol Disord. 2019, Vol. 12. https://doi.org/10.1177/1756286419878340

Barin L, Kamm CP, Salmen A, Dressel H, Calabrese P, Pot C, Schippling S, Gobbi C, Müller S, Chan A, Rodgers S, Kaufmann M, Ajdacic-Gross V, Steinemann N, Kesselring J, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry. How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis. Mult Scler. 2019 Jan 18. doi: 10.1177/1352458518823955

Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kümpfel T, Linker RA, Paul F, Stangel M, Tackenberg B, Bergh FT, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Tumani H, Gold R, Hemmer B; German Competence Network of Multiple Sclerosis. Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. JAMA Neurol. 2019 Apr 29. doi: 10.1001/jamaneurol.2019.0905. 

Hoepner R, Bagnoud M, Pistor M, Salmen A, Briner M, Synn H, Schrewe L, Guse K, Ahmadi F, Demir S, Laverick L, Gresle M, Worley P, Reichardt HM, Butzkueven H, Gold R, Metz I, Lühder F, Chan A. Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis. Acta Neuropathol. 2019 Apr 27. doi: 10.1007/s00401-019-02018-8. 

Briner M, Bagnoud M, Miclea A, Friedli C, Diem L, Chan A, Hoepner R and Salmen A. Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age. Ther Adv Neurol Disord. 2019, 12. DOI: 10.1177/1756285619843450.

Miclea A, Salmen A, Wiest R, Zoehner G, Wagner F, Hoepner A, Schrewe L, Evangelopoulos ME, Kamber N, Chan A, Hoepner R. Prediction of conversion to multiple sclerosis using the 2017 McDonald and 2016 MAGNIMS criteria in patients with clinically isolated syndrome: a retrospective single-centre study. Ther Adv Neurol Disord. 2019, 12. DOI: 10.1177/1756286419835652.

Kaufmann M, Kuhle J, Puhan MA, Kamm CP, Chan A, Salmen A, Kesselring J, Calabrese P, Gobbi C, Pot C, Steinemann N, Rodgers S and von Wyl V; for the Swiss Multiple Sclerosis Registry (SMSR). Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland. Multiple Sclerosis Journal - Experimental, Translational and Clinical; October-December 2018, 1–10; DOI: 10.1177/2055217318814562

Barin L, Kaufmann M, Salmen A, Kamm CP, Gobbi C, Kuhle J, Pot C, Chan A, Czaplinski A, Ajdacic-Gross V, Rodgers S, Kesselring J, Puhan MA, von Wyl V, for the Swiss Multiple Sclerosis Registry. Patterns of care for Multiple Sclerosis in a setting of universal care access: A cross-sectional study. Mult Scler Relat Dis. 28 (2019) 17–25. https://doi.org/10.1016/j.msard.2018.11.033

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Then Bergh F, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H and Salmen A, on behalf of German Competence Network Multiple Sclerosis (KKNMS). Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). J Neurol 2018, https://doi.org/10.1007/s00415-018-9142-y

Miclea A*, Salmen A*, Zoehner GC, Panos CI, Briner M, Chan A, Evangelopoulos EM*, Hoepner R*. Age-dependent variation of female preponderance across different phenotypes of multiple sclerosis: a retrospective cross-sectional study. CNS Neurosci Ther. 2018; DOI: 10.1111/cns.13083. *contributed equally

Wagner F*, Grunder L*, Hakim A, Wiest D, Kamber N, Horn MP, Muellner J, Hoepner R, Wiest R, Metz I, Chan A, Salmen A. Rebound after fingolimod and a single daclizumab injection in a patient retrospectively diagnosed with NMO spectrum disorder – MRI apparent diffusion coefficient maps in differential diagnosis of demyelinating CNS disorders. Front Neurol. 2018; 9:782. doi: 10.3389/fneur.2018.00782. *contributed equally

Barin L, Salmen A*, Disanto G*, Babačića H, Calabrese P, Chan A, Kamm CP, Kesselring J, Kuhle J, Gobbi C, Pot C, Puhan MA, von Wyl V, for the Swiss Multiple Sclerosis Registry (SMSR). The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most? Mult Scler Relat Dis. 2018 Jul; 25: 112–121. DOI: 10.1016/j.msard.2018.07.013 *contributed equally

Evangelopoulos ME, Miclea A, Schrewe L, Briner M, Salmen A, Engelhardt B, Huwiler A, Chan A, Hoepner R. Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod. CNS Neurosci Ther. 2018 Jun 13. doi: 10.1111/cns.12992

Hoepner R*, Miclea A*, Popovic J, Kamber N, Chan A, Salmen A. Immunoglobulin levels may aid in prediction of treatment response in anti-CD20 treatment of Multiple Sclerosis. Clinical & Translational Neuroscience 2018. DOI: 10.1177/2514183X18764792 *contributed equally

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke J, Kümpfel T, Linker RA, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F. Association of smoking but not HLA-DRB1*15:01, APOE, or body mass index with brain atrophy in early multiple sclerosis. Mult Scler. 2018. DOI: 10.1177/1352458518763541

Von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A. Treatment choices and neuropsychological symptoms in a large cohort of early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2018;5:e446. doi:10.1212/NXI.0000000000000446

Rummel C, Aschwanden F, McKinley R, Wagner F, Salmen A, Chan A and Wiest R. A Fully Automated Pipeline for Normative Atrophy in Patients with Neurodegenerative Disease. Front Neurol. 2018 Jan 24;8:727. doi: 10.3389/fneur.2017.00727

Thiel S, Leypoldt F, Röpke L, Wandinger KP, Kümpfel T, Aktas O, von Bismarck O, Salmen A, Ambrosius B, Ellrichmann G, Antony G, Dankowski T, Ziegler A, Stahmann A, Meyer C, Eichstädt K, Buckow K, Meißner T, Thibaut J, Khil L, Berger K, Gold R, Hellwig K. Neuroimmunological registries in Germany. Neurology International Open 2018; 2: E25–E39, DOI https://doi.org/10.1055/s-0043-108830

Salmen A. Clinical commentary on “Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab”. Mult Scler. 2018, Vol. 24(3) 360-362. DOI: 10.1177/1352458517717810

Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J; Swiss Multiple Sclerosis Cohort Study Group (Kuhle J, Lorscheider J, Yaldizli Ö, Derfuss T, Kappos L, Disanto G, Zecca C, Gobbi C, Benkert P, Achtnichts L, Nedeltchev K, Kamm CP, Salmen A, Chan A, Lalive PH, Pot C, Schluep M, Granziera C, Du Pasquier R, Müller S, Vehoff J). Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017 Jun;81(6):857-870. doi: 10.1002/ana.24954

Hagström IT, Schneider R, Bellenberg B, Salmen A, Weiler F, Köster O, Gold R, Lukas C. Relevance of early cervical cord volume loss in the disease evolution of clinically isolated syndrome and early multiple sclerosis: a 2-year follow-up study. J Neurol. 2017 Jul;264(7):1402-1412. doi: 10.1007/s00415-017-8537-5

Kinner M, Hoepner R, Klotz P, Prehn C, Faissner S, Salmen A, Linker RA, Gold R, Chan A. Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple Sclerosis. CNS Neurosci Ther. 2016Dec;22(12):1019-1022. doi: 10.1111/cns.12652

Hoepner R, Kolb EM, Dahlhaus S, Hellwig K, Adams O, Kleiter I, Salmen A, Schneider R, Lukas C, Chan A, Berger JR, Gold R. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2016 Sep; doi:10.1177/1352458516667241

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B. Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Sci Adv. 2016 Jun 17;2(6):e1501678. doi: 10.1126/sciadv.1501678

Recke A, Oei A, Hübner F, Fechner K, Graf J, Hagenah J, May C, Woitalla D, Salmen A, Zillikens D, Gold R, Schlumberger W, Schmidt E. Parkinson's disease and multiple sclerosis are not associated with autoantibodies against structural proteins of the dermal-epidermal junction. Br J Dermatol. 2016 Mar 12. DOI: 10.1111/bjd.14538

Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue EW, Sprenger T, Stippich C, Derfuss T, Louvion JF, Kamm CP, Mattle HP, Lotter C, Du Pasquier R, Schluep M, Pot C, Lalive PH, Yaldizli Ö, Gobbi C, Kappos L, Kuhle J; SMSC Scientific Board. Collaborators: Ramseier S, Achtnichts L, Findling O, Saxer J, Nedeltchev K, Remonda L, Boxheimer L, Kuhle J, Kappos L, Yaldizli Ö, Derfuss T, Sprenger T, Limberg M, Scheerer I, Orleth A, Treppke F, Beregi E, Stippich C, Reinhardt J, Fellner I, Würfel J, Radue EW, Thoeni A, Palatini A, Pauli-Magnus C, Fabbro T, Benkert P, Roesler A, Mechati S, Louvion JF, Kamm C, Chan A, Mattle H, Salmen A, Kaeser M, Wagner F, Verma R, Lalive P, Di Marco M, Haller S, Lovblad KO, Du Pasquier R, Schluep M, Pot C, Granziera C, Hagmann P, Maeder P, Gobbi C, Zecca C, Disanto G, Tschuor S, Cianfoni A, Müller S, Vehoff J, Weber J, Lotter C. The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLoS One. 2016 Mar 31;11(3):e0152347. doi: 10.1371/journal.pone.0152347

Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H. Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie - Substanzspezifische Relevanz und aktuelle Handlungsempfehlungen. Nervenarzt. 2016 Feb 29. DOI: 10.1007/s00115-016-0077-1

Salmen A, von Ahsen N, Trampe AK, Hoepner R, Plavina T, Subramanyam M, Kuesters G, Gold R, Chan A. Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2016 Feb. DOI: 10.1177/2055217316630008

Dankowski T, Buck D, Andlauer TF, Antony G, Bayas A, Bechmann L, Berthele A, Bettecken T, Chan A, Franke A, Gold R, Graetz C, Haas J, Hecker M, Herms S, Infante-Duarte C, Jöckel KH, Kieseier BC, Knier B, Knop M, Kümpfel T, Lichtner P, Lieb W, Lill CM, Limmroth V, Linker RA, Loleit V, Meuth SG, Moebus S, Müller-Myhsok B, Nischwitz S, Nöthen MM, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Strauch K, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Waldenberger M, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Hemmer B, Ziegler A; German Competence Network for Multiple Sclerosis (KKNMS). Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. Genet Epidemiol. 2015 Oct 26. DOI: 10.1002/gepi.21933

Schrewe L, Lill CM, Liu T, Salmen A, Gerdes LA, Guillot-Noel L, Akkad D, Blaschke P, Graetz C, Hoffjan S, Kroner A, Demir S, Böhme A, Rieckmann P, ElAli A, Hagemann N, Hermann D, Cournu-Rebeix I, Zipp F, Kümpfel T, Buttmann M, Zettl UK, Fontaine B, Bertram L, Gold R, Chan A. Investigation of sex-specific effects of apolipoprotein E on severity of EAE and MS. J Neuroinflammation. 2015 Dec 16;12(1):234. doi: 10.1186/s12974-015-0429-y

Kohlmann R*, Salmen A*, Chan A, Knabbe C, Diekmann J, Brockmeyer N, Skaletz-Rorowski A, Michalik C, Gold R, Überla K. Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis. Mult Scler. 2015 Dec;21(14):1823-32. DOI: 10.1177/1352458515576984 *contributed equally.

Salmen A, Chan A. [New therapeutic options in multiple sclerosis]. Fortschr Neurol Psychiatr. 2015Mar;83(3):174-86. DOI: 10.1055/s-0034-1399247. 

Grey, née Cotte S*, Salmen, née Stroet A*, von Ahsen N, Starck M, Winkelmann A, Zettl UK, Comabella M, Montalban X, Zipp F, Fleischer V, Kruse N, Gold R, Chan A. Lack of efficacy of Mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-centre, retrospective analysis. J Neuroimmunol. 2015 Jan 15;278:277-9. DOI: 10.1016/j.jneuroim.2014.11.017 *contributed equally. 

de la Hera B, Urcelay E, Brassat D, Chan A, Vidal-Jordana A, Salmen A, Villar LM, Alvarez-Cermeño JC, Izquierdo G, Fernández O, Oliver B, Saiz A, Ara JR, Vigo AG, Arroyo R, Meca V, Malhotra S, Fissolo N, Horga A, Montalban X, Comabella M. Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. Neurol Neuroimmunol Neuroinflamm. 2014 Dec 11;1(4):e47. DOI: 10.1212/NXI.0000000000000047

Fleischer V, Salmen A, Kollar S, Weyer V, Siffrin V, Chan A, Zipp F, Luessi F. Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients. J Clin Neurol. 2014 Oct;10(4):289-95. doi: 10.3988/jcn.2014.10.4.289

Salmen A, Linker R, Gold R. Neue Behandlungsziele bei Multipler Sklerose: Mögliche neuroprotektive Aspekte etablierter und neuer Immuntherapeutika. Akt Neurol 2014; 41:392-396.

Salmen A, Gold R, Chan A. Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system. Clin Exp Immunol. 2014 May;176(2):135-48. DOI: 10.1111/cei.12258

Hoepner R, Faissner S, Salmen A, Gold R, Chan A. Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis. J Cent Nerv Syst Dis. 2014 Apr 28;6:41-9. doi: 10.4137/JCNSD.S14049

Salmen A, Gold R. Mode of action and clinical studies with fumarates in multiple sclerosis. Exp Neurol. 2014Dec;262 Pt A:52-6. DOI: 10.1016/j.expneurol.2014.02.015

Stroet A, Linker RA, Gold R. Advancing therapeutic options in multiple sclerosis with neuroprotective properties. J Neural Transm. 2013 Sep;120 Suppl 1:S49-53. doi: 10.1007/s00702-013-1037-6

Stroet A, Trampe N, Chan A. Treatment failure of intrathecal baclofen and supra-additive effect of nabiximols in multiple sclerosis-related spasticity: a case report. Ther Adv Neurol Disord. 2013 May;6(3):199-203. doi: 10.1177/1756285613475835

Décard BF, von Ahsen N, Grunwald T, Streit F, Stroet A, Niggemeier P, Schottstedt V, Riggert J, Gold R, Chan A. Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 Dec;83(12):1170-3. doi: 10.1136/jnnp-2012-303068

Elliott C, Lindner M, Arthur A, Brennan K, Jarius S, Hussey J, Chan A, Stroet A, Olsson T, Willison H, Barnett SC, Meinl E, Linington C. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain. 2012 Jun;135(Pt 6):1819-33. doi: 10.1093/brain/aws105

Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology. 2012 May 29;78(22):1736-42. doi: 10.1212/WNL.0b013e3182583022

Stroet A, Gold R, Chan A. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology. 2012 Mar 20;78(12):933; author reply 933-4. doi: 10.1212/01.wnl.0000413366.14351.54

Stroet A, Hemmelmann C, Starck M, Zettl U, Dörr J, Friedemann P, Flachenecker P, Fleischer V, Zipp F, Nückel H, Kieseier BC, Ziegler A, Gold R, Chan A. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord. 2012 Mar;5(2):75-9. DOI: 10.1177/1756285611433318

Meyer C, Ansorge N, Siglienti I, Salmen S, Stroet A, Nückel H, Dührsen U, Ritter PR, Schmidt WE, Gold R, Chan A. [Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia]. Nervenarzt. 2010 Dec;81(12):1483-9. doi: 10.1007/s00115-010-3041-5

Stroet A, Gold R. Therapie mit Interferon ß-1b nach Plasmapheresebehandlung bei klinisch isoliertem Syndrom [Therapy with Interferon β-1b after Plasmapheresis of a Patient with Clinically Isolated Syndrome] Akt Neurol 2009; 36: S281-S283.